Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery

Phase 2 Recruiting 40 enrolled Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for postoperative pain management in abdominal surgery.

Timeline

Start: 2025-12
Primary completion: 2026-02
Completion: 2026-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HL-1186	Unknown	—	Oral

Indications

No indication recorded.